Comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190 vs 3mc Syndrome 1 C0796059
Clinical comparison between 3 Phosphoglycerate Dehydrogenase Deficiency and 3mc Syndrome 1 for differential diagnosis and treatment planning.
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
A rare metabolic disorder impairing the body's ability to produce serine, an essential amino acid. It primarily affects the nervous system, causing developmental delay, seizures, and movement difficulties. Management includes serine supplementation and anticonvulsants as needed.
3mc Syndrome 1 C0796059
A rare genetic disorder affecting multiple body systems, causing distinctive facial features, developmental delays, and growth issues. Management involves multidisciplinary care.
6 comparison axes
Onset
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
0-5
3mc Syndrome 1 C0796059
0-0
Onset patterns differ
Severity
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
severe
3mc Syndrome 1 C0796059
moderate
Different severity levels
Chronic
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
Chronic
3mc Syndrome 1 C0796059
Chronic
Differing course
Communicable
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
No
3mc Syndrome 1 C0796059
No
Different transmission
Body System
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3mc Syndrome 1 C0796059
congenital
Same/different system
Category
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
metabolic
3mc Syndrome 1 C0796059
genetic
Different category
Bottom line
3-phosphoglycerate-dehydrogenase-deficiency-C0580190 and 3mc-syndrome-1-C0796059 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3mc Syndrome 1 C0796059 | Discriminating power |
|---|---|---|---|
| Seizures and movement | Developmental delay, seizures, and movement difficulty are described. | Seizures are not a supplied defining feature. | Moderate |
| Facial features and growth | Distinctive facial features are not the supplied hallmark. | Distinctive facial features and growth issues are described. | Moderate |
| Developmental delay | Delay occurs with a primarily neurologic metabolic picture. | Delay occurs with congenital multisystem findings. | Low |
When to favor each condition
Choose 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 when
Early neurologic illness suggesting impaired serine production
Matches the severe metabolic nervous-system description.
Moderate
Amino-acid testing suggests low serine
Supports specialist evaluation; it does not alone confirm the disorder.
Moderate
Onset from birth through early childhood
The supplied onset range is 0-5 years.
Low
Choose 3mc Syndrome 1 C0796059 when
Congenital facial features with growth issues
Matches the supplied congenital syndrome description.
Moderate
Multiple congenital findings needing coordinated care
Management is described as multidisciplinary.
Moderate
Findings evident at birth without a serine-metabolism pattern
The supplied onset is congenital.
Low
How key tests differ
| Test | 3 Phosphoglycerate Dehydrogenase Deficiency C0580190 | 3mc Syndrome 1 C0796059 | Interpretation |
|---|---|---|---|
| Plasma or CSF amino acids | Low serine may be found; no cutoff is established here. | Not expected to define this syndrome. | An abnormal result requires specialist confirmation. |
| Genetic testing | May support a serine-biosynthesis disorder. | May support 3MC syndrome 1. | Variant meaning must be interpreted clinically. |
| Clinical dysmorphology and development review | Focus on seizures, movement, and development. | Focus on face, growth, and multiple systems. | The pattern helps prioritize testing. |
Prognosis comparison
3 Phosphoglycerate Dehydrogenase Deficiency C0580190
- Outcome
- Long-term outcome is not established; neurologic burden may be substantial.
- Factors
- Seizures, development, and response to directed serine therapy may matter.
3mc Syndrome 1 C0796059
- Outcome
- Outcome is not established; supplied severity is moderate and course chronic.
- Factors
- Congenital findings, growth, development, and coordinated care may matter.
Time frame: Both are described as chronic; exact milestones are unavailable.
Individual complications and support matter. Neither is communicable.
Complications comparison
| Complication | Presentation |
|---|---|
| Seizures | A described neurologic feature. Not established from the supplied data. Anticonvulsant choice is individualized; no dose is given. |
| Growth difficulty | Not the main supplied feature. Growth issues are described. Severity varies and needs clinical monitoring. |
| Developmental disability | Delay may accompany severe neurologic disease. Delay may occur despite a moderate severity label. Individual outcome is not established here. |
Patient education highlights
- HighDifferent conditions
One affects serine production; the other is a congenital genetic multisystem syndrome.
- HighResults versus diagnosis
Amino-acid or genetic findings need clinician and genetics interpretation.
- MediumOngoing care
Serine supplementation or seizure care, and multidisciplinary follow-up, are clinician-directed; no doses are provided.